Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis
There were significant baseline differences between the treatment groups, so this study represents an unadjusted comparison between the results obtained with different biologics in second-line treatment for Crohn's disease. In patients with CD who have failed a first anti-TNF, the highest rate of clinical remission at 12 weeks was obtained with second-line IFX and UST whilst vedolizumab showed lower efficacy. UST demonstrated the most favorable long-term treatment persistence at 1 year.
Authors
- Cosmin Alexandru Ciora
- Letiţia Ţugui
- Corina Meianu
- Cristian Tieranu (ORCID: https://orcid.org/0000-0001-5348-0341)
- Mircea Diculescu (ORCID: https://orcid.org/0000-0003-0073-5990)
- Ana-Maria Sîngeap (ORCID: https://orcid.org/0000-0001-5621-548X)
- Horia Minea (ORCID: https://orcid.org/0000-0002-7736-8140)
- A. Bota (ORCID: https://orcid.org/0000-0001-7460-3830)
- Doina Istrătescu (ORCID: https://orcid.org/0000-0001-6960-4599)
- Anca Victorita Trifan (ORCID: https://orcid.org/0000-0001-9144-5520)
- Carmen Monica Preda
- Remus Popescu
- Ana-Maria Buzuleac
- T G Stroie
- L Negreanu
- Alina Tantau
- Andreea-Maria Cazimirovitz
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Clinical Emergency Hospital Bucharest (RO)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Emergency University (US)
- Spitalul Clinic Judeţean de Urgenţe "Sf. Spiridon" Iaşi (RO)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3390/jcm15083029
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00